Global TIGIT Therapies Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global TIGIT Therapies Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
TIGIT Therapies report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global TIGIT Therapies market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Cell Carcinoma and Solid Tumor are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for TIGIT Therapies industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, TIGIT Therapies key companies include Roche, Merck, AstraZeneca, Arcus, Astellas, BeiGene, BMS, Junshi Biosciences and Innovent Biologics, etc. Roche, Merck, AstraZeneca are top 3 players and held % share in total in 2022.
TIGIT Therapies can be divided into Monotherapy and Combination Therapy, etc. Monotherapy is the mainstream product in the market, accounting for % share globally in 2022.
TIGIT Therapies is widely used in various fields, such as Cell Carcinoma and Solid Tumor, etc. Cell Carcinoma provides greatest supports to the TIGIT Therapies industry development. In 2022, global % share of TIGIT Therapies went into Cell Carcinoma filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global TIGIT Therapies market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report

Roche
Merck
AstraZeneca
Arcus
Astellas
BeiGene
BMS
Junshi Biosciences
Innovent Biologics
Mereo BioPharma
Seattle Genetics
Hengrui Medicine
Compugen
Segment by Type
Monotherapy
Combination Therapy
Cell Carcinoma
Solid Tumor
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the TIGIT Therapies market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, TIGIT Therapies introduction, etc. TIGIT Therapies Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of TIGIT Therapies market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
North America, Europe and Asia Pacific are the key regions for TIGIT Therapies industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, TIGIT Therapies key companies include Roche, Merck, AstraZeneca, Arcus, Astellas, BeiGene, BMS, Junshi Biosciences and Innovent Biologics, etc. Roche, Merck, AstraZeneca are top 3 players and held % share in total in 2022.
TIGIT Therapies can be divided into Monotherapy and Combination Therapy, etc. Monotherapy is the mainstream product in the market, accounting for % share globally in 2022.
TIGIT Therapies is widely used in various fields, such as Cell Carcinoma and Solid Tumor, etc. Cell Carcinoma provides greatest supports to the TIGIT Therapies industry development. In 2022, global % share of TIGIT Therapies went into Cell Carcinoma filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global TIGIT Therapies market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report

By Company
Roche
Merck
AstraZeneca
Arcus
Astellas
BeiGene
BMS
Junshi Biosciences
Innovent Biologics
Mereo BioPharma
Seattle Genetics
Hengrui Medicine
Compugen
Segment by Type
Monotherapy
Combination Therapy
Segment by Application
Cell Carcinoma
Solid Tumor
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the TIGIT Therapies market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2029).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, TIGIT Therapies introduction, etc. TIGIT Therapies Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of TIGIT Therapies market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.
